Globe Newswire

TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) is pleased to announce the results of the vote on directors at its May 13, 2024 annual shareholders' meeting. Each of the fifteen nominees listed in the Corporation's management proxy circular dated March 27, 2024 was elected as a director. Voting was conducted by ballot with the following voting results:

CHIHUAHUA, Mexico, May 13, 2024 (GLOBE NEWSWIRE) -- GCC, S.A.B. de C.V. (BMV: GCC* or, “the Company”), a leading producer of cement and concrete in the United States and Mexico, today announced that the General Shareholders’ Meeting held on April 25, 2024, declared a Ps. 1.5369 dividend per share, which comes from the balance of the net earnings on a tax basis corresponding to the fiscal year 2013 and previous years.

The declared dividend will be paid on May... (continue reading...)

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rivian Automotive, Inc. (NASDAQ: RIVN) between March 1, 2023 and February 21, 2024, both dates inclusive (the “Class Period”), of the important June 18, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Rivian securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees... (continue reading...)

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024.

HMPL-306 is a novel... (continue reading...)

— Almost half a million people diagnosed each year across the globe —

— Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui’s camrelizumab, promoting the immune response against tumor cells —

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”)... (continue reading...)